Prosecution Insights
Last updated: May 29, 2026

Glaxosmithkline Biologicals SA

13 pending office actions • 5 art units • 12 examiners • 0 of 13 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days

Portfolio Summary

13
Total Pending OAs
8
Non-Final OAs
5
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 13 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

12
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 13 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (12)Due ≤ 30 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
9
Medium (69%)
2
Easy (15%)
2
Unknown (15%)

Rejection Statute Mix

BucketCases
§103 only6 (46%)
§102 only3 (23%)
§112 only2 (15%)
No statute on record2 (15%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

13
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

130 h
Manual time on pending OAs
26 h
Time saved (low, 20%)
46 h
Time saved (mid, 35%)
1.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SHAHNAN SHAH, KHATOL S 2 62.6% +53.8%
RONEY, CELESTE A 1 62.3% +18.0%
JACKSON-TONGUE, LAKIA J 1 68.8% +20.4%
CORNELIUS, CLAIRE ADRIENNE 1
HINES, JANA A 1 53.2% +39.3%
OGUNBIYI, OLUWATOSIN A 1 63.3% +42.1%
COFFA, SERGIO 1 61.0% +33.3%
MORGAN, BAILEY MICHELLE 1 57.1% +56.3%
CHEONG, CHEOM-GIL 1 65.0% +54.4%
DUFFY, PATRICIA ANN 1 52.4% +34.7%

Interview Candidates (10)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17588425 VACCINE SHAHNAN SHAH, KHATOL S 86d overdue
18131557 IMMUNOGENIC COMPOSITION HINES, JANA A 85d overdue
18402174 BIOCONJUGATES MADE FROM RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROCARYOTIC CELLS JACKSON-TONGUE, LAKIA J 60d overdue
17632270 PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE CHEONG, CHEOM-GIL 51d overdue
18683531 LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME RONEY, CELESTE A 43d overdue
18001498 MODIFIED EXOTOXIN A PROTEINS OGUNBIYI, OLUWATOSIN A 43d overdue
18001551 Shigella-Tetravalent (Shigella4V) Bioconjugate SHAHNAN SHAH, KHATOL S 43d overdue
17854377 PNEUMOCOCCAL CAPSULAR SACCHARIDE CONJUGATE VACCINE MORGAN, BAILEY MICHELLE 30d overdue

Top Art Units

Art UnitApps
1645 8
1672 2
1612 1
1658 1
1671 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18683531 LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME RONEY, CELESTE A 1612 §103 Non-Final OA 43d overdue Pending Feb 14, 2024
18402174 BIOCONJUGATES MADE FROM RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROCARYOTIC CELLS JACKSON-TONGUE, LAKIA J 1645 §112 Non-Final OA 60d overdue Pending Jan 02, 2024
18262073 Therapeutic Viral Vaccine CORNELIUS, CLAIRE ADRIENNE 1672 Other Non-Final OA 49d overdue Pending Jul 19, 2023
18131557 IMMUNOGENIC COMPOSITION HINES, JANA A 1645 §102 Final Rejection 85d overdue Pending Apr 06, 2023
18001498 MODIFIED EXOTOXIN A PROTEINS OGUNBIYI, OLUWATOSIN A 1645 §112 Non-Final OA 43d overdue Pending Dec 12, 2022
18001551 Shigella-Tetravalent (Shigella4V) Bioconjugate SHAHNAN SHAH, KHATOL S 1645 §103 Non-Final OA 43d overdue Pending Dec 12, 2022
18008771 DOCK TAG SYSTEM COFFA, SERGIO 1658 Other Final Rejection 28d Pending Dec 07, 2022
17854377 PNEUMOCOCCAL CAPSULAR SACCHARIDE CONJUGATE VACCINE MORGAN, BAILEY MICHELLE 1645 §103 Final Rejection 30d overdue Pending Jun 30, 2022
17632270 PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE CHEONG, CHEOM-GIL 1645 §103 Final Rejection 51d overdue Pending Feb 02, 2022
17588425 VACCINE SHAHNAN SHAH, KHATOL S 1645 §103 Non-Final OA 86d overdue Pending Jan 31, 2022
17628667 QUANTIFICATION OF BIOCONJUGATE GLYCOSYLATION DUFFY, PATRICIA ANN 1645 §102 Non-Final OA 30d overdue Pending Jan 20, 2022
17618283 MUCOSAL VACCINE FORMULATIONS LI, BAO Q 1671 §102 Non-Final OA 16d overdue Pending Dec 10, 2021
17262098 ANTIGEN PURIFICATION METHOD WANG, RUIXUE 1672 §103 Final Rejection 99d overdue Pending Jan 21, 2021

Managing Glaxosmithkline Biologicals SA's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month